Pinned
We’re excited to introduce Origin-1: a generative AI platform for de novo antibody design against "zero-prior" epitopes.
Origin-1 has been successfully validated against four targets: COL6A3, AZGP1, CHI3L2, and IL36RA
Key Highlights:
-Fewer than 100 design attempts per target
GIF










